Search

GA in Practice Background

Editorial Feature:

GA in Practice

How data and personal experience are evolving the treatment of geographic atrophy.

Multimodal Imaging for Biomarker Detection in GA Patients

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Show Description +

What imaging biomarkers signal a higher risk of rapid progression in geographic atrophy, and how might AI eventually help track treatment effect in real time? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review specific multimodal imaging approaches at the point of diagnosis, the field's growing comfort with earlier intervention with complement inhibitors, and the technology gaps still standing in the way of measuring GA progression on an individual level.

Posted: 7/01/2026

Keywords:

multimodal imaging

•

Biomarkers

•

detection

•

Geographic Atrophy (GA)

•

Diagnostics/Imaging

•

risk

•

progression

•

Artificial Intelligence

•

AI

•

diagnosis

•

early intervention

•

complement inhibition

•

inhibitor

•

complement

•

complement factors

•

Technology

Up Next

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Talking to Patients About Treatment Risks

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA in the Presence of Dense Cataract, Followed by CNV Development

GA in the Presence of Dense Cataract, Followed by CNV Development

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Delayed Complement Inhibition Therapy per Patient Request

Delayed Complement Inhibition Therapy per Patient Request

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Back to All Videos

Multimodal Imaging for Biomarker Detection in GA Patients

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

What imaging biomarkers signal a higher risk of rapid progression in geographic atrophy, and how might AI eventually help track treatment effect in real time? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, review specific multimodal imaging approaches at the point of diagnosis, the field's growing comfort with earlier intervention with complement inhibitors, and the technology gaps still standing in the way of measuring GA progression on an individual level.

Posted: 7/01/2026

Keywords:

multimodal imaging

•

Biomarkers

•

detection

•

Geographic Atrophy (GA)

•

Diagnostics/Imaging

•

risk

•

progression

•

Artificial Intelligence

•

AI

•

diagnosis

•

early intervention

•

complement inhibition

•

inhibitor

•

complement

•

complement factors

•

Technology

Please log in to leave a comment.